FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158825065> ?p ?o ?g. }

• W2158825065 endingPage "503" @default.
• W2158825065 startingPage "492" @default.
• W2158825065 abstract "Aim This U.S. multicenter open‐label study used a noninferiority trial design to assess the efficacy of tadalafil 20 mg to treat erectile dysfunction (ED) in the black American and Hispanic groups compared with a reference group of Caucasians. A secondary objective was to demonstrate the efficacy and safety of tadalafil 20 mg in various populations of men with ED. Methods A total of 1,911 patients with ED were enrolled into eight predefined groups: (1–3) Caucasian (Reference group), Black American, or Hispanic patients, ≤65 years of age with no diabetes mellitus or depression; (4) patients with depression, ≤65 years of age, no diabetes; (5) patients with diabetes, ≤65 years of age, no depression; (6) patients >65 years of age, no diabetes or depression; (7) patients who met enrollment criteria but were not included in any other group; and (8) patients with ED due to traumatic spinal cord injury. The study had a 4‐week run‐in period, followed by a 12‐week treatment period with tadalafil taken as needed, up to one dose/day, prior to sexual activity. Change from baseline to endpoint in the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) was used to determine noninferiority of groups 2 and 3 from group 1. Secondary efficacy measures included other IIEF domains and Sexual Encounter Profile (SEP). Results Noninferiority analyses based on the EF domain score showed that tadalafil was as efficacious in the Hispanic and Black American groups as in the Reference group. Patients in each of the eight groups had a significant change from baseline (P < 0.001) in the IIEF EF domain score and positive responses to SEP Questions 1–5. The most common treatment‐emergent adverse events reported by patients in all eight groups were headache, nasal congestion, dyspepsia, flushing, and back pain. Conclusion Tadalafil 20 mg was as efficacious in the Hispanic and black American groups as in the Caucasian/Reference group. Tadalafil was efficacious and well tolerated in each of the groups studied in this trial. Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, and Wong DG. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med 2006;3:492–503." @default.
• W2158825065 created "2016-06-24" @default.
• W2158825065 creator A5006375093 @default.
• W2158825065 creator A5018075996 @default.
• W2158825065 creator A5019825677 @default.
• W2158825065 creator A5030525796 @default.
• W2158825065 creator A5053548238 @default.
• W2158825065 creator A5069888995 @default.
• W2158825065 creator A5071598910 @default.
• W2158825065 creator A5082351091 @default.
• W2158825065 date "2006-05-01" @default.
• W2158825065 modified "2023-09-27" @default.
• W2158825065 title "ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Safety of Tadalafil Across Ethnic Groups and Various Risk Factors in Men with Erectile Dysfunction: Use of a Novel Noninferiority Study Design" @default.
• W2158825065 cites W1497481744 @default.
• W2158825065 cites W1991713014 @default.
• W2158825065 cites W2007239126 @default.
• W2158825065 cites W2020501414 @default.
• W2158825065 cites W2026664968 @default.
• W2158825065 cites W2045693224 @default.
• W2158825065 cites W2061953311 @default.
• W2158825065 cites W2068920057 @default.
• W2158825065 cites W2090529329 @default.
• W2158825065 cites W2121939064 @default.
• W2158825065 cites W2124981826 @default.
• W2158825065 cites W2128882483 @default.
• W2158825065 cites W2129831689 @default.
• W2158825065 cites W2137948715 @default.
• W2158825065 cites W2304572562 @default.
• W2158825065 cites W2333113037 @default.
• W2158825065 cites W4249523014 @default.
• W2158825065 doi "https://doi.org/10.1111/j.1743-6109.2006.00209.x" @default.
• W2158825065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16681475" @default.
• W2158825065 hasPublicationYear "2006" @default.
• W2158825065 type Work @default.
• W2158825065 sameAs 2158825065 @default.
• W2158825065 citedByCount "25" @default.
• W2158825065 countsByYear W21588250652012 @default.
• W2158825065 countsByYear W21588250652013 @default.
• W2158825065 countsByYear W21588250652015 @default.
• W2158825065 countsByYear W21588250652016 @default.
• W2158825065 countsByYear W21588250652017 @default.
• W2158825065 countsByYear W21588250652018 @default.
• W2158825065 countsByYear W21588250652020 @default.
• W2158825065 crossrefType "journal-article" @default.
• W2158825065 hasAuthorship W2158825065A5006375093 @default.
• W2158825065 hasAuthorship W2158825065A5018075996 @default.
• W2158825065 hasAuthorship W2158825065A5019825677 @default.
• W2158825065 hasAuthorship W2158825065A5030525796 @default.
• W2158825065 hasAuthorship W2158825065A5053548238 @default.
• W2158825065 hasAuthorship W2158825065A5069888995 @default.
• W2158825065 hasAuthorship W2158825065A5071598910 @default.
• W2158825065 hasAuthorship W2158825065A5082351091 @default.
• W2158825065 hasConcept C126322002 @default.
• W2158825065 hasConcept C134018914 @default.
• W2158825065 hasConcept C139719470 @default.
• W2158825065 hasConcept C162324750 @default.
• W2158825065 hasConcept C1862650 @default.
• W2158825065 hasConcept C2776867660 @default.
• W2158825065 hasConcept C2779929075 @default.
• W2158825065 hasConcept C2780816001 @default.
• W2158825065 hasConcept C555293320 @default.
• W2158825065 hasConcept C71924100 @default.
• W2158825065 hasConceptScore W2158825065C126322002 @default.
• W2158825065 hasConceptScore W2158825065C134018914 @default.
• W2158825065 hasConceptScore W2158825065C139719470 @default.
• W2158825065 hasConceptScore W2158825065C162324750 @default.
• W2158825065 hasConceptScore W2158825065C1862650 @default.
• W2158825065 hasConceptScore W2158825065C2776867660 @default.
• W2158825065 hasConceptScore W2158825065C2779929075 @default.
• W2158825065 hasConceptScore W2158825065C2780816001 @default.
• W2158825065 hasConceptScore W2158825065C555293320 @default.
• W2158825065 hasConceptScore W2158825065C71924100 @default.
• W2158825065 hasIssue "3" @default.
• W2158825065 hasLocation W21588250651 @default.
• W2158825065 hasLocation W21588250652 @default.
• W2158825065 hasOpenAccess W2158825065 @default.
• W2158825065 hasPrimaryLocation W21588250651 @default.
• W2158825065 hasRelatedWork W1898711703 @default.
• W2158825065 hasRelatedWork W1999638102 @default.
• W2158825065 hasRelatedWork W2080911515 @default.
• W2158825065 hasRelatedWork W2090709439 @default.
• W2158825065 hasRelatedWork W2162680380 @default.
• W2158825065 hasRelatedWork W2364188297 @default.
• W2158825065 hasRelatedWork W2381883906 @default.
• W2158825065 hasRelatedWork W2747565125 @default.
• W2158825065 hasRelatedWork W2752228605 @default.
• W2158825065 hasRelatedWork W2981515574 @default.
• W2158825065 hasVolume "3" @default.
• W2158825065 isParatext "false" @default.
• W2158825065 isRetracted "false" @default.
• W2158825065 magId "2158825065" @default.
• W2158825065 workType "article" @default.